Condition: Netherton Syndrome · Sponsor: Azitra Inc.
The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.
This description comes directly from the study's public registry record.
Travis Whitfill · 203-646-6446 · clinicaltrials@azitrainc.com
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Completed |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06137157